Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 2.4%. By the end of trading, Valeant Pharmaceuticals International fell $2.39 (-3.1%) to $73.69 on average volume. Throughout the day, 1,638,394 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,351,800 shares. The stock ranged in price between $73.40-$76.31 after having opened the day at $75.34 as compared to the previous trading day's close of $76.08. Other companies within the Drugs industry that declined today were: Progenics Pharmaceuticals ( PGNX), down 13.7%, Astex Pharmaceuticals ( ASTX), down 12.7%, Aastrom Biosciences ( ASTM), down 12.7% and Idera Pharmaceuticals ( IDRA), down 11.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $23.1 billion and is part of the health care sector. Shares are up 27.3% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

On the positive front, MediciNova ( MNOV), down 21.9%, Regeneron Pharmaceuticals ( REGN), down 10.3%, IGI ( IG), down 8.0% and iBio ( IBIO), down 7.0% , were all gainers within the drugs industry with Sarepta Therapeutics ( SRPT) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%